After a bidding war erupted between Pfizer and Novo Nordisk over the fledgling obesity drugmaker, Metsera sided with its original suitor in a final agreement announced late Friday evening.

The Phase III results impressed Guggenheim Partners analysts both in terms of efficacy and safety. If approved, atacicept ...

During a press conference to announce a drug price deal for GLP-1s, President Donald Trump asked for more details about the ...

The highest dose of Eli Lilly’s eloralintide led to 20.1% weight loss after 48 weeks in a Phase II trial, exceeding analyst ...

Darzalex Faspro’s approval for smoldering multiple myeloma could allow for earlier intervention and reduce the risk of ...

The FDA awards a second round of Commissioner’s National Priority vouchers to six larger biopharma companies. And this time, ...

The agreement will also secure a $150 price for future weight loss pills from Novo Nordisk and Eli Lilly—at least initially.

The search continues for a new leader for the FDA’s Center for Drug Evaluation and Research after George Tidmarsh resigned on ...

Pressure from the FTC and Pfizer is building around Novo Nordisk’s bid to snatch obesity biotech Metsera: The antitrust ...

The company reported $200 million in net losses for the third quarter, but an aggressive and highly successful cost-cutting ...

In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based ...

The court’s decision allows Metsera to walk away from its previous acquisition agreement with Pfizer in favor of Novo Nordisk ...